Drug delivery device demands drive increased SHL investment in Taiwan

SHL Continues to Expand Taiwan Facilities to Support Auto Injector Production

With the growing demand for auto injectors and increasing number of biologics coming to market, SHL continues to invest in expanding core manufacturing capabilities such as CNC, Molding and Automation. Taoyuan, Taiwan, May 14, 2011 --(PR.com)-- SHL has just completed an additional expansion of its Nan Kan 6 facility located in northern Taiwan to ensure that adequate production capacity can be maintained for its OEM/ODM customers. CNC, Molding, and Automation related production have been added to the facility, expanding on their support for these key in-house capabilities. In particular, this facility will house extensive CNC lines which will be utilized by SHL Automation to support production of automated testing and assembly equipment for their medical devices. In addition, these CNC lines will be utilized by SHL Technologies to support its growing need for precision machined components and modules. Frank Isaksson, GM for Taiwan, commented on this growth stating: "Demand for auto injectors continues to rise as the number of biologics coming to market steadily increases. The simple fact is that SHL will continue to expand our production capabilities over the next few years and will also find new ways to enhance our utilization of current machinery, people and resources. Several of our biotechnology and pharmaceutical customers are now working with us on multiple projects. With continued expansion in Taiwan, our new facility in the USA and future expansion in Europe we will have the depth of capabilities and resources needed to maintain our leadership position in the auto injector market, including production of other drug delivery devices such as pen injectors and inhalers systems." SHL currently has six production facilities in Taiwan related to SHL Medical and plans to acquire space at two of its larger facilities as needed. Further expansion related to production facilities has also taken place in North America with SHL's newest facility based in South Florida focusing on the final packaging and assembly of drug delivery devices, such as the Molly Auto Injector. SHL will continue to develop additional in-house capabilities to further enhance the range of services they can offer to their clients.

About SHL SHL is the world's largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 1,600 staff globally (over 1000 staff in Taiwan), with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia. SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of "next generation" drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.

Our organization consists of three distinct group companies:

SHL Medical  Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies.

SHL Healthcare  Develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies  Provides contract manufacturing and engineering services for the production of complex medtech and industrial products.